ABSTRACT
We evaluated the performance of the Abbott BinaxNOW™ Covid-19 rapid antigen test to detect virus among persons, regardless of symptoms, at a public plaza site of ongoing community transmission. Titration with cultured clinical SARS-CoV-2 yielded a human observable threshold between 1.6×104-4.3×104 viral RNA copies (cycle threshold (Ct) of 30.3-28.8 in this assay). Among 878 subjects tested, 3% (26/878) were positive by RT-PCR, of which 15/26 had a Ct<30, indicating high viral load. 40% (6/15) of Ct<30 were asymptomatic. Using this Ct<30 threshold for Binax-CoV2 evaluation, the sensitivity of the Binax-CoV2 was 93.3% (14/15), 95% CI: 68.1-99.8%, and the specificity was 99.9% (855/856), 95% CI: 99.4-99.9%.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by UCSF, the Chan Zuckerberg Biohub, the Chan Zuckerberg Initiative, the San Francisco Latino Task Force, and a private donor. LR was funded by T32 AI060530, and SS was funded by F31AI150007.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UCSF Committee on Human Research determined that the study met criteria for public health surveillance. All participants provided informed consent for dual testing.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Raw numbers used to calculate Binax-CoV2 specificity were updated. Previously: 862/863 (99.9%) mistakenly included 7 Binax-CoV2 tests that were invalid. Updated: 855/856 (99.9%) correctly represents the numbers of valid tests used in this calculation. Figure 2 was revised to indicate asymptomatic and symptomatic persons.
Data Availability
All data referred to in the manuscript is included in the figures of the manuscript. Supplemental material (Binax-CoV2 reader training guide) is included in the link.
